<DOC>
	<DOCNO>NCT01840007</DOCNO>
	<brief_summary>In western country , melanoma represent major mistake public health frequency , lethality increase incidence . Surgery cure melanoma diagnose early . In case , exist risk recurrence lymph node visceral . At stage visceral metastasis , prognosis melanoma catastrophic , median survival 6 month . Indeed , reference chemotherapy dacarbazine induces limit response rate 10-20 % , ipilimumab authorize second intention , response rate 10 % , available treatment n't superior efficiency . Metformin oral antidiabetic biguanides family act induce activation AMPK , molecule inactivate many cancer include melanoma . In agreement data , several preclinical study suggest metformin antineoplastic activity . In case melanoma , study publish recently show metformin inhibits proliferation melanoma cell vitro confirm part result laboratory ( INSERM U895 ) .</brief_summary>
	<brief_title>Pilot Study Evaluating Efficacy Safety Metformin Melanoma</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Major patient metastatic melanoma ( stage IIIC nonrésécable surgically curable stage IV classification AJCC ) progression firstline treatment vemurafenib chemotherapy , noneligible nonresponders ipilimumab . Metastases measurable RECIST criterion . Hematologic , renal hepatic appropriate function . Negative pregnancy test . Patients symptomatic brain metastasis Performans Status ( PS ) &gt; 2 . Patients carcinomatous meningitis . Pregnant breathfeeding woman . Patients contraindication metformine . HIV infection , active infection HBV HCV . Patients already treat metformin context diabetes .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2013</verification_date>
</DOC>